H

Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566

Watchlist Manager
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Watchlist
Price: 29.92 CNY -0.56% Market Closed
Market Cap: 27.4B CNY
Have any thoughts about
Hubei Jumpcan Pharmaceutical Co Ltd?
Write Note

Hubei Jumpcan Pharmaceutical Co Ltd
Net Income (Common)

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

Hubei Jumpcan Pharmaceutical Co Ltd
Net Income (Common) Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Net Income (Common) CAGR 3Y CAGR 5Y CAGR 10Y
H
Hubei Jumpcan Pharmaceutical Co Ltd
SSE:600566
Net Income (Common)
ÂĄ2.8B
CAGR 3-Years
21%
CAGR 5-Years
11%
CAGR 10-Years
14%
H
Hansoh Pharmaceutical Group Company Ltd
HKEX:3692
Net Income (Common)
ÂĄ3.3B
CAGR 3-Years
8%
CAGR 5-Years
11%
CAGR 10-Years
N/A
Zhangzhou Pientzehuang Pharmaceutical Co Ltd
SSE:600436
Net Income (Common)
ÂĄ3.1B
CAGR 3-Years
9%
CAGR 5-Years
18%
CAGR 10-Years
23%
Jiangsu Hengrui Pharmaceuticals Co Ltd
SSE:600276
Net Income (Common)
ÂĄ5.4B
CAGR 3-Years
-5%
CAGR 5-Years
2%
CAGR 10-Years
14%
Yunnan Baiyao Group Co Ltd
SZSE:000538
Net Income (Common)
ÂĄ4.3B
CAGR 3-Years
5%
CAGR 5-Years
3%
CAGR 10-Years
6%
S
Sichuan Biokin Pharmaceutical Co Ltd
SSE:688506
Net Income (Common)
-ÂĄ780.5m
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

Hubei Jumpcan Pharmaceutical Co Ltd
Glance View

Market Cap
27.6B CNY
Industry
Pharmaceuticals

In the bustling landscape of China's pharmaceutical industry, Hubei Jumpcan Pharmaceutical Co Ltd stands as a key player, weaving together tradition and modernity. Founded in 1951, this company has curated a journey of evolution—from its roots in the rich tapestry of traditional Chinese medicine to its current standing as a significant contributor to the healthcare sector. Core to Jumpcan's operation is its production and distribution of a diverse array of pharmaceutical products that span across various therapeutic areas, including digestive health, dermatology, and respiratory care. With an adept focus on over-the-counter medications and prescription drugs, Jumpcan effectively meets the health needs of a broad demographic, leveraging both the enduring appeal of traditional remedies and the growing demand for contemporary medical solutions. The business prowess of Jumpcan is deeply entwined with its strategy of innovation and adherence to quality standards, ensuring its pharmaceutical offerings are not only effective but also safe for consumption. Anchored in robust R&D initiatives, the company continues to enhance its product line, incorporating advanced technology and scientific research to produce medicines that align with global quality benchmarks. Furthermore, Jumpcan thrives on an extensive distribution network that spans across China, ensuring widespread accessibility of its products. By maintaining a keen understanding of the market dynamics and consumer preferences, Jumpcan artfully aligns its operations to capitalize on both domestic and international opportunities, thus solidifying its financial standing and perpetuating its growth within the dynamic corridors of the pharmaceutical industry.

Intrinsic Value
47.78 CNY
Undervaluation 37%
Intrinsic Value
Price
H

See Also

What is Hubei Jumpcan Pharmaceutical Co Ltd's Net Income (Common)?
Net Income (Common)
2.8B CNY

Based on the financial report for Sep 30, 2024, Hubei Jumpcan Pharmaceutical Co Ltd's Net Income (Common) amounts to 2.8B CNY.

What is Hubei Jumpcan Pharmaceutical Co Ltd's Net Income (Common) growth rate?
Net Income (Common) CAGR 10Y
14%

Over the last year, the Net Income (Common) growth was 10%. The average annual Net Income (Common) growth rates for Hubei Jumpcan Pharmaceutical Co Ltd have been 21% over the past three years , 11% over the past five years , and 14% over the past ten years .

Back to Top